DexCom Total Cost of Revenue decreased by 5.4% to $441.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.2%, from $447.00M to $441.60M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 24.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $178.00M | $203.30M | $225.60M | $230.70M | $246.70M | $275.40M | $273.90M | $278.90M | $324.90M | $351.70M | $377.90M | $359.10M | $377.60M | $400.40M | $457.70M | $447.00M | $468.30M | $477.90M | $466.90M | $441.60M |
| QoQ Change | — | +14.2% | +11.0% | +2.3% | +6.9% | +11.6% | -0.5% | +1.8% | +16.5% | +8.2% | +7.4% | -5.0% | +5.2% | +6.0% | +14.3% | -2.3% | +4.8% | +2.0% | -2.3% | -5.4% |
| YoY Change | — | — | — | — | +38.6% | +35.5% | +21.4% | +20.9% | +31.7% | +27.7% | +38.0% | +28.8% | +16.2% | +13.8% | +21.1% | +24.5% | +24.0% | +19.4% | +2.0% | -1.2% |